KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares OutstandingShares Repurchased
Ratios

Royalty Pharma (RPRX) Receivables Refunds (2019 - 2025)

Historic Receivables Refunds for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $29.3 million.

  • Royalty Pharma's Receivables Refunds rose 875.5% to $29.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.3 million, marking a year-over-year increase of 875.5%. This contributed to the annual value of $29.3 million for FY2025, which is 875.5% up from last year.
  • Royalty Pharma's Receivables Refunds amounted to $29.3 million in Q4 2025, which was up 875.5% from $28.9 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Receivables Refunds registered a high of $29.3 million during Q4 2025, and its lowest value of $6.5 million during Q1 2021.
  • For the 5-year period, Royalty Pharma's Receivables Refunds averaged around $20.5 million, with its median value being $21.8 million (2023).
  • Its Receivables Refunds has fluctuated over the past 5 years, first surged by 23981.57% in 2021, then surged by 64.75% in 2024.
  • Over the past 5 years, Royalty Pharma's Receivables Refunds (Quarter) stood at $15.0 million in 2021, then soared by 31.58% to $19.8 million in 2022, then increased by 13.35% to $22.4 million in 2023, then rose by 20.31% to $27.0 million in 2024, then increased by 8.76% to $29.3 million in 2025.
  • Its last three reported values are $29.3 million in Q4 2025, $28.9 million for Q3 2025, and $27.7 million during Q2 2025.